(Q21092309)

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Current consensus guidelines for treatment of neurocysticercosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Bias in meta-analysis detected by a simple, graphical test

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Statistical aspects of the analysis of data from retrospective studies of disease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Meta-analysis in clinical trials

19 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

19 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Neurocysticercosis: a major cause of neurological disease worldwide

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Cysticercosis: an emerging parasitic disease.

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Neurocysticercosis: current knowledge and advances

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Control of Taenia solium cysticercosis/taeniosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Meta-analysis: Methods, strengths, weaknesses, and political uses

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Controlling the risk of spurious findings from meta-regression.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Assessing the quality of randomized controlled trials. Current issues and future directions

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

The importance of quality of primary studies in producing unbiased systematic reviews

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Drug treatment of neurocysticercosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Effect of anticysticercal treatment on the prognosis of epilepsy in neurocysticercosis: a pilot trial

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Therapy of parenchymal brain cysticercosis with praziquantel.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Albendazole versus praziquantel in the treatment of cerebral cysticercosis: clinical evaluation.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Therapy for neurocysticercosis. Comparison between albendazole and praziquantel

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265431

Neurocysticercosis--is the elimination of parasites beneficial?

30 May 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000194

Single-day praziquantel versus 1-week albendazole for neurocysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000194

Plasma levels of praziquantel decrease when dexamethasone is given simultaneously.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000194

Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000194

Spontaneous radiographic disappearance of cerebral cysticercosis: three cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000194

Single-day praziquantel therapy for neurocysticercosis

21 January 2018

1 reference

12 December 2020

Dexamethasone increases plasma levels of albendazole

1 reference

12 December 2020

Cysticercotic encephalitis: a severe form in young females

1 reference

12 December 2020

Is the course of neurocysticercosis modified by treatment with antihelminthic agents?

1 reference

12 December 2020

Neurocysticercosis: a review

1 reference

12 December 2020

Phenytoin and carbamazepine decreased oral bioavailability of praziquantel

1 reference

12 December 2020

High-dose praziquantel for neurocysticercosis: efficacy and tolerability

1 reference

12 December 2020

Therapy for Neurocysticercosis

1 reference

12 December 2020